Showing results (821-830 of 2,357) with videos related to

Sort By:
Pageof 236
Clinical Neuropharmacology|July 14, 2015
Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease: Clinical Experience After 3 Years' Follow-upAntoniya Todorova, Michael Samuel, Richard G Brown, et al.
Clinical Neuropharmacology|July 14, 2015
Five Patients With Burning Mouth Syndrome in Whom an Antidepressant (Serotonin-Noradrenaline Reuptake Inhibitor) Was Not Effective, but Pregabalin Markedly Relieved PainMikiko Ito, Tatsuya Tokura, Keizo Yoshida, et al.
Clinical Neuropharmacology|August 2, 2001
Neurobiology and clinical pharmacology of obsessive-compulsive disorderJ Micallef, O Blin
Clinical Neuropharmacology|August 2, 2001
SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective studyG Dell'Agnello, R Ceravolo, A Nuti, et al.
Clinical Neuropharmacology|June 8, 2001
Quick titration of pergolide in cotreatment with domperidone is safe and effectiveP A Jansen, R M Herings, M M Samson, et al.
Clinical Neuropharmacology|April 3, 2003
Treatment of dystoniaJennifer G Goldman, Cynthia L Comella
Clinical Neuropharmacology|February 5, 2003
Clozapine in Parkinson's disease psychosis: 5-year follow-up reviewColin Klein, Jacob Gordon, Lea Pollak, et al.
Clinical Neuropharmacology|June 5, 2003
Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodoneRafael Stryjer, Rael D Strous, Faina Bar, et al.
Clinical Neuropharmacology|June 5, 2003
Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugsMireille Gony, Maryse Lapeyre-Mestre, Jean-Louis Montastruc, et al.
Clinical Neuropharmacology|June 5, 2003
High-dose ropinirole in advanced Parkinson's disease with severe dyskinesiasS Cristina, R Zangaglia, F Mancini, et al.
Pageof 236